Dr. Tom Wu is a co-founder of Apros Therapeutics, and leads Chemistry and Pre-Clinical Development. Dr. Wu specializes in tissue-specific drug design, which has led to the discovery of several clinical stage innate immune agonists for treatment of cancer and as vaccine adjuvant. Dr. Wu received his B.Sc. in Chemistry and Biochemistry at The University of British Columbia, Ph.D. at The Scripps Research Institute, and previously held the positions of Senior Research Chemist at Merck Frosst and Associate Director at Novartis/GNF.

Dr. Ron Weitzman leads Clinical Development at Apros Therapeutics. Dr. Weitzman is a US trained board certified medical oncologist and has worked in the biopharmaceutical industry since 1999. Over his career he has worked in all areas of clinical development including phase 1, 2 and 3 clinical trials. Dr. Weitzman has drug development experience in both solid and hematological malignancies and has interacted extensively with FDA, EMEA, Canadian and Japanese health authorities. In his most recent FTE role at Exelixis, he oversaw cabozantinib's (XL184) development in prostate cancer with two ongoing phase 3 registrational studies. Over the years Dr. Weitzman has managed both large and small groups and very much enjoys mentoring colleagues. In 2014, he founded Weitzman Consulting Group LLC which provides consulting services in all areas of Oncology drug development.

Ms. Trinh Le leads Clinical Operations at Apros Therapeutics. Ms. Le has over 25 years of experience in clinical operations, her unique set of experiences has demonstrated success in all operational aspects of global clinical trials from early to late stage for drug and biologic products across multiple therapeutic areas. Ms. Le received her B.A. in Urban Studies at University of California, San Diego and her Masters of Business Administration at University of Redlands. She has held senior positions at several biotech/pharmaceuticals and contract research companies.

Mr. Keane leads Business Development at Apros Therapeutics and is a seasoned life sciences executive with an extensive track record in business development and financial transactions for emerging biopharmaceutical companies. He has experience as CBO, COO and CEO of several Venture Capital funded companies, including officer roles in publicly traded companies. Mr. Keane has raised over $420 million in equity capital in the last two decades and has helped generate more than $450 million in non-dilutive partner revenues to fund drug discovery programs. He was responsible for negotiating multiple acquisitions, alliances including licenses, distributions agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. He holds a Bachelor of Arts in English Literature from San Diego State University.

Dr. Pamela M. Klein is Principal of PMK BioResearch offering advisory and strategic consulting for the biotechnology industry and venture firms. She is a member of the Board of Directors of Argenx, Patrys, Springbank and I-Mab Biopharma. Dr. Klein has served as Chief Medical Officer for multiple successful biotech companies as well as Vice President, Development, Genentech where she led the Development for a portfolio of drugs. Prior to this, she served as Research Director for the National Cancer Institute-Navy Breast Care Center that she co-founded while at the NIH. Dr. Klein is trained in Internal Medicine and Medical Oncology.

Dr. Sheng Ding is currently the Dean and Bayer Distinguished Professor in the School of Pharmaceutical Sciences at Tsinghua University. He is also the founding Institute Director of Global Health Drug Discovery Institute in Beijing, a joint venture by Tsinghua University and the Bill & Melinda Gates Foundation. Dr. Ding also holds a joint appointment as William K. Bowes, Jr. Distinguished Investigator at the Gladstone Institutes, and Professor at Department of Pharmaceutical Chemistry, University of California San Francisco. He obtained his B.S. in chemistry with honors from Caltech in 1999, and a Ph.D. in chemistry from The Scripps Research Institute in 2003. Before moving to back to China, Ding was an Assistant Professor and then Associate Professor of Chemistry at Scripps from 2003 to 2011, and then Senior Investigator/Professor at Gladstone/UCSF from 2011 to 2016. Dr. Ding has pioneered on developing and applying innovative chemical approaches to stem cell biology and regeneration, with a focus on discovering and characterizing novel small molecules that can control various cell fate/function, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues. Ding has published over 150 research articles, reviews and book chapters, and made several seminal contributions to the stem cell field and drug discovery. Ding is a cofounder of several biotechnology companies.